NewAmsterdam Pharma Co N.V.
NAMS · XNASCIK 1936258fmd_0JJ33CRX0EHBX73ANDNJPCXHENManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 19 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 103 | 14 | 46 | 23 |
| Research and development | 29 | 87 | 159 | 151 | 142 |
| Selling, general and administrative | 6 | 20 | 38 | 70 | 106 |
| Total operating expenses | 35 | 106 | 197 | 222 | 248 |
| Compensation and benefits | – | 7 | 14 | 33 | 41 |
| Operating income | (35) | (4) | (183) | (176) | (226) |
| Interest expense | 0 | 0 | – | – | – |
| Interest and investment income | – | – | 11 | 17 | 28 |
| Income before taxes | (42) | (23) | (177) | (242) | (204) |
| Income tax expense | – | – | 0 | (0) | – |
| Net income from continuing operations | – | – | (177) | (242) | – |
| Net income | (42) | (23) | (177) | (242) | (204) |